Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · TRDA · as of Jun 9, 2026
Activity summary
Buy transactions
17
P-Purchase only
Sell transactions
19
12 Months
Buy/Sell ratio
0.89
Buy/Sell (by trades)
Overall sentiment
Entrada Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
TRDA insider buying and selling by quarter
TRDA insider selling · TRDA insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · TRDA ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
TRDA executive sell shares · TRDA board member insider trading · TRDA insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 20, 2026 | Zeiher Bernhardt G Director | Purchase | 5,000 | $29K | Form 4 |
| May 4, 2026 | Sethuraman Natarajan President, Research & Develop. | Sale | 25,907 | $399K | Form 4 |
| May 4, 2026 | Dowden Nathan J President & COO | Option | 15,000 | $26K | Form 4 |
| May 4, 2026 | Dowden Nathan J President & COO | Sale | 15,000 | $230K | Form 4 |
| Apr 1, 2026 | WENTWORTH KORY JAMES CFO | Sale | 2,500 | $32K | Form 4 |
| Mar 9, 2026 | Dowden Nathan J President & COO | Sale | 3,116 | $41K | Form 4 |
| Mar 10, 2026 | Dowden Nathan J President & COO | Sale | 11,894 | $155K | Form 4 |
| Mar 9, 2026 | WENTWORTH KORY JAMES CFO | Sale | 5,089 | $66K | Form 4 |
| Mar 10, 2026 | WENTWORTH KORY JAMES CFO | Sale | 11,388 | $148K | Form 4 |
| Mar 4, 2026 | WENTWORTH KORY JAMES CFO | Sale | 7,988 | $98K | Form 4 |
| Mar 1, 2026 | Doshi Dipal CEO · Director | Award | 139,400 | — | Form 4 |
| Mar 2, 2026 | Doshi Dipal CEO · Director | Other | 9,869 | $115K | Form 4 |
| Mar 3, 2026 | Doshi Dipal CEO · Director | Other | 19,181 | $225K | Form 4 |
| Mar 1, 2026 | WENTWORTH KORY JAMES CFO | Award | 44,600 | — | Form 4 |
| Mar 2, 2026 | WENTWORTH KORY JAMES CFO | Other | 2,939 | $34K | Form 4 |
| Mar 3, 2026 | WENTWORTH KORY JAMES CFO | Other | 5,712 | $67K | Form 4 |
| Mar 1, 2026 | Dowden Nathan J President & COO | Award | 55,800 | — | Form 4 |
| Mar 2, 2026 | Dowden Nathan J President & COO | Other | 7,223 | $84K | Form 4 |
| Mar 3, 2026 | Dowden Nathan J President & COO | Other | 14,038 | $165K | Form 4 |
| Mar 1, 2026 | Sethuraman Natarajan President, Research & Develop. | Award | 55,800 | — | Form 4 |
| Mar 2, 2026 | Sethuraman Natarajan President, Research & Develop. | Other | 3,898 | $45K | Form 4 |
| Mar 3, 2026 | Sethuraman Natarajan President, Research & Develop. | Other | 7,577 | $89K | Form 4 |
| Nov 21, 2025 | WENTWORTH KORY JAMES CFO | Sale | 8,910 | $89K | Form 4 |
| Nov 20, 2025 | BAKER BROS. ADVISORS LP 10 percent owner | Purchase | 13,082 | $119K | Form 4 |
| Nov 20, 2025 | BAKER BROS. ADVISORS LP 10 percent owner | Purchase | 13,386 | $121K | Form 4 |
Sethuraman Natarajan
President, Research & Develop.
Date
May 4
Shares
25,907
Price
$15.39
Value
$399K
Sethuraman Natarajan
President, Research & Develop.
Date
Mar 1
Shares
55,800
Price
—
Value
—
Sethuraman Natarajan
President, Research & Develop.
Date
Mar 2
Shares
3,898
Price
$11.66
Value
$45K
Sethuraman Natarajan
President, Research & Develop.
Date
Mar 3
Shares
7,577
Price
$11.76
Value
$89K
BAKER BROS. ADVISORS LP
10 percent owner
Date
Nov 20
Shares
13,082
Price
$9.07
Value
$119K
BAKER BROS. ADVISORS LP
10 percent owner
Date
Nov 20
Shares
13,386
Price
$9.07
Value
$121K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About TRDA insider trading
TRDA insider trades
Entrada Therapeutics, Inc. (TRDA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including BAKER BROS. ADVISORS LP (10 percent owner), WENTWORTH KORY JAMES (CFO), PARMAR KUSH (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. TRDA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Entrada Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
TRDA insider trading · 5 questionsThe insiders of Entrada Therapeutics, Inc. (TRDA) include executives and directors such as BAKER BROS. ADVISORS LP (10 percent owner), WENTWORTH KORY JAMES (CFO), PARMAR KUSH (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026